middle.news
AdAlta Taps FDA Expertise to Fast-Track CAR-T Therapy for Mesothelioma
8:17am on Monday 25th of May, 2026 AEST
•
Biotechnology
Read Story
AdAlta Taps FDA Expertise to Fast-Track CAR-T Therapy for Mesothelioma
8:17am on Monday 25th of May, 2026 AEST
Key Points
Engagement with Dark Horse Consulting for FDA pre-IND support
Focus on aligning manufacturing and trial design with FDA expectations
BZDS1901 shows durable complete tumour responses in refractory mesothelioma
Potential access to accelerated regulatory pathways and commercial benefits
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE